AbbVie (ABBV) Receivables - Net (2012 - 2026)
AbbVie (ABBV) posted quarterly Receivables - Net of $12.5 billion for Q1 2026, little changed year-over-year from $12.5 billion in Q1 2025, and down 0.87% quarter-over-quarter from $12.6 billion in Q4 2025.
AbbVie (ABBV) Receivables - Net (2012 - 2026) Analysis & Trends
AbbVie (ABBV) has reported Receivables - Net for 15 consecutive years, with $12.5 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Receivables - Net changed 0.02% year-over-year to $12.5 billion; the TTM figure through Mar 2026 stood at $12.5 billion (changed 0.02% YoY), while the FY2025 annual figure was $12.6 billion, up 15.29% from the prior year.
- Receivables - Net declined to $12.5 billion in Q1 2026 per ABBV's latest filing, from $12.6 billion in the prior quarter.
- Across five years, Receivables - Net topped out at $12.8 billion in Q3 2025 and bottomed at $10.7 billion in Q1 2022.
- Historically, Receivables - Net has averaged $11.7 billion across 5 years, with a median of $11.5 billion in 2023.
- Annual changes were most pronounced in 2022 — Receivables - Net increased 15.75% — and 2024, when it decreased 2.12%.
- AbbVie's Receivables - Net stood at $11.3 billion in 2022, then retreated by 0.88% to $11.2 billion in 2023, then dropped by 2.12% to $10.9 billion in 2024, then grew by 15.29% to $12.6 billion in 2025, then slipped by 0.87% to $12.5 billion in 2026.
- Business Quant data shows ABBV's Receivables - Net at $12.5 billion in Q1 2026, $12.6 billion in Q4 2025, and $12.8 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 654.04 Bn | 633.28 Bn | 17.26 Bn |
| 2 | AbbVie | 470.61 Bn | 464.04 Bn | 12.70 Bn |
| 3 | Merck | 379.00 Bn | 371.86 Bn | 12.21 Bn |
| 4 | Novartis Ag | 303.30 Bn | 295.61 Bn | 11.24 Bn |
| 5 | Astrazeneca | 258.47 Bn | 253.57 Bn | 12.86 Bn |
| 6 | Amgen | 237.78 Bn | 223.79 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 183.75 Bn | 180.57 Bn | 6.22 Bn |
| 8 | Pfizer | 160.91 Bn | 149.21 Bn | 10.94 Bn |
| 9 | Gsk | 106.07 Bn | 101.90 Bn | 8.24 Bn |
| 10 | Sanofi | 55.31 Bn | 47.93 Bn | 10.79 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 13.82 Bn |
| Jun 30, 2026 | 13.82 Bn |
| Mar 31, 2026 | 12.48 Bn |
| Mar 31, 2026 | 12.48 Bn |
| Dec 31, 2025 | 12.59 Bn |
| Dec 31, 2025 | 12.59 Bn |
| Sep 30, 2025 | 12.77 Bn |
| Sep 30, 2025 | 12.77 Bn |
| Jun 30, 2025 | 12.64 Bn |
| Jun 30, 2025 | 12.64 Bn |
| Mar 31, 2025 | 12.48 Bn |
| Mar 31, 2025 | 12.48 Bn |
| Dec 31, 2024 | 10.92 Bn |
| Dec 31, 2024 | 10.92 Bn |
| Sep 30, 2024 | 11.47 Bn |
| Sep 30, 2024 | 11.47 Bn |
| Jun 30, 2024 | 11.72 Bn |
| Jun 30, 2024 | 11.72 Bn |
| Mar 31, 2024 | 11.95 Bn |
| Mar 31, 2024 | 11.95 Bn |